6CM
IRLA

683 Capital Management’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

683 Capital Management’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,191
Closed -$798K – 260
2025
Q4 		$798K Buy
+1,191
New +$599K 0.03% 160

Other funds holding IRLA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

683 Capital Management's IRLA Position: Q1 2026 in Review

683 Capital Management sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q1 2026, closing a stake of 1,191 shares — an estimated $798K sold.

683 Capital Management first reported a position in IRLA in Q4 2025 and held it in 1 quarter. The position peaked at $798K in Q4 2025. 43 funds tracked by Wall St. Rank hold IRLA as of Q1 2026.

  • 683 Capital Management reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q1 2026 after selling out during the quarter.
  • 683 Capital Management sold 1,191 IRulya Therapeutics Inc. Common Stock shares in Q1 2026, an estimated $798K.
  • 683 Capital Management first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2025 and held it in 1 quarter.
  • 683 Capital Management's IRulya Therapeutics Inc. Common Stock position peaked at $798K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.